GS
MRTX

GTS Securities’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

GTS Securities’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-47,716
Closed -$2.8M – 4615
2023
Q4 		$2.8M Buy
47,716
+1,091
+2% +$61.3K ﹤0.01% 1408
2023
Q3 		$2.03M Buy
46,625
+30,451
+188% +$1.09M ﹤0.01% 1504
2023
Q2 		$584K Buy
+16,174
New +$666K 0.02% 598

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GTS Securities's MRTX Position: Q1 2024 in Review

GTS Securities sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 47,716 shares — an estimated $2.8M sold.

GTS Securities first reported a position in MRTX in Q2 2023 and held it in 3 quarters. The position peaked at $2.8M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • GTS Securities reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • GTS Securities sold 47,716 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.8M.
  • GTS Securities first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2023 and held it in 3 quarters.
  • GTS Securities's Mirati Therapeutics, Inc. Common Stock position peaked at $2.8M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on GTS Securities's 13F filing for Q1 2024, filed 15 May 2024.